Formulation of inactivated influenza vaccines for providing effective cross-protection by intranasal vaccination in mice
Identifieur interne : 001E03 ( Main/Exploration ); précédent : 001E02; suivant : 001E04Formulation of inactivated influenza vaccines for providing effective cross-protection by intranasal vaccination in mice
Auteurs : Shin-Ichi Tamura [Japon] ; Hideki Asanuma [Japon] ; Yuji Ito [Japon] ; Keiko Yoshizawa [Japon] ; Takashi Nagamine [Japon] ; Chikara Aizawa [Japon] ; Takeshi Kurata [Japon]Source :
- Vaccine [ 0264-410X ] ; 1994.
English descriptors
- Teeft :
- Antigenic, Antigenic drift, Bronchoalveolar, Bronchoalveolar site, Bronchoalveolar wash, Bronchoalveolar washes, Challenge virus, Cholera, Cholera toxin, Drift virus vaccine, Drift viruses, Earliest virus, Earliest virus strains, Hin1, Immunization, Infection, Influenza, Influenza vaccine, Influenza virus infection, Influenza viruses, Inoculation, Intranasal, Intranasal vaccination, Intranasally, Latest virus strains, Lethal dose, Lung infection, Many changes, Mouse, Nasal, Nasal infection, Nasal site, Nasal vaccination, Nasal wash, Original antigenic, Other details, Other hand, Present results, Primary immunization, Primary inoculation, Primary vaccine, Regimen, Respiratory tract, Second antigen, Second immunization, Second inoculation, Second vaccine, Subsequent inoculation, Subtype, Tamura, Titre, Vaccinated, Vaccinated mice, Vaccination, Vaccine, Vaccine strains, Virus, Virus challenge, Virus infection, Virus strains, Virus titres, Virus vaccine.
Abstract
Abstract: Attempts were made to formulate an inactivated influenza vaccine to provide effective cross-protection by intranasal vaccination in mice. Mice were immunized with a nasal site-restricted volume of various HA vaccines (split-product virus vaccines), prepared from some of the H1N1 subtype viruses which circulated in humans from 1934 to 1986, together with cholera toxin B subunit (CTB) as an adjuvant. Four weeks later, they were challenged intranasally with a lethal dose of the earliest H1N1 virus strain, A/PR/8/34 (PR8) or the latest virus strain, A/Yamagata/120/86 (Yamagata/86). The adjuvant-combined vaccines, prepared from drift H1N1 viruses, A/Kumamoto/37/79 and A/Bangkok/10/83, provided a higher degree of cross-protection against a challenge with Yamagata/86 than with PR8. A booster with another drift virus vaccine given 4 weeks after the primary vaccination increased the protection against Yamagata/86; the effect was higher when mice were vaccinated with a later strain as the second antigen than when boosted with PR8. These results suggest that vaccination with a later virus strain followed by another later strain in a two-dose nasal vaccination regimen gives effective cross-protection against the current epidemic virus strains.
Url:
DOI: 10.1016/0264-410X(94)90094-9
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001303
- to stream Istex, to step Curation: 001303
- to stream Istex, to step Checkpoint: 000B74
- to stream Main, to step Merge: 001E85
- to stream Main, to step Curation: 001E03
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Formulation of inactivated influenza vaccines for providing effective cross-protection by intranasal vaccination in mice</title><author><name sortKey="Tamura, Shin Ichi" sort="Tamura, Shin Ichi" uniqKey="Tamura S" first="Shin-Ichi" last="Tamura">Shin-Ichi Tamura</name></author><author><name sortKey="Asanuma, Hideki" sort="Asanuma, Hideki" uniqKey="Asanuma H" first="Hideki" last="Asanuma">Hideki Asanuma</name></author><author><name sortKey="Ito, Yuji" sort="Ito, Yuji" uniqKey="Ito Y" first="Yuji" last="Ito">Yuji Ito</name></author><author><name sortKey="Yoshizawa, Keiko" sort="Yoshizawa, Keiko" uniqKey="Yoshizawa K" first="Keiko" last="Yoshizawa">Keiko Yoshizawa</name></author><author><name sortKey="Nagamine, Takashi" sort="Nagamine, Takashi" uniqKey="Nagamine T" first="Takashi" last="Nagamine">Takashi Nagamine</name></author><author><name sortKey="Aizawa, Chikara" sort="Aizawa, Chikara" uniqKey="Aizawa C" first="Chikara" last="Aizawa">Chikara Aizawa</name></author><author><name sortKey="Kurata, Takeshi" sort="Kurata, Takeshi" uniqKey="Kurata T" first="Takeshi" last="Kurata">Takeshi Kurata</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:8D1DC3B6C29BAF110C167CE2FC616DC687931CE3</idno><date when="1994" year="1994">1994</date><idno type="doi">10.1016/0264-410X(94)90094-9</idno><idno type="url">https://api.istex.fr/ark:/67375/6H6-R0HTHJ49-6/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">001303</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001303</idno><idno type="wicri:Area/Istex/Curation">001303</idno><idno type="wicri:Area/Istex/Checkpoint">000B74</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000B74</idno><idno type="wicri:doubleKey">0264-410X:1994:Tamura S:formulation:of:inactivated</idno><idno type="wicri:Area/Main/Merge">001E85</idno><idno type="wicri:Area/Main/Curation">001E03</idno><idno type="wicri:Area/Main/Exploration">001E03</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Formulation of inactivated influenza vaccines for providing effective cross-protection by intranasal vaccination in mice</title><author><name sortKey="Tamura, Shin Ichi" sort="Tamura, Shin Ichi" uniqKey="Tamura S" first="Shin-Ichi" last="Tamura">Shin-Ichi Tamura</name><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Pathology, National Institute of Health, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author><author><name sortKey="Asanuma, Hideki" sort="Asanuma, Hideki" uniqKey="Asanuma H" first="Hideki" last="Asanuma">Hideki Asanuma</name><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Pathology, National Institute of Health, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author><author><name sortKey="Ito, Yuji" sort="Ito, Yuji" uniqKey="Ito Y" first="Yuji" last="Ito">Yuji Ito</name><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Pathology, National Institute of Health, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author><author><name sortKey="Yoshizawa, Keiko" sort="Yoshizawa, Keiko" uniqKey="Yoshizawa K" first="Keiko" last="Yoshizawa">Keiko Yoshizawa</name><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Pathology, National Institute of Health, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author><author><name sortKey="Nagamine, Takashi" sort="Nagamine, Takashi" uniqKey="Nagamine T" first="Takashi" last="Nagamine">Takashi Nagamine</name><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Technology, Kitasato Institute, 5-9-1 Shirokane, Minato-ku, Tokyo 108</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author><author><name sortKey="Aizawa, Chikara" sort="Aizawa, Chikara" uniqKey="Aizawa C" first="Chikara" last="Aizawa">Chikara Aizawa</name><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Technology, Kitasato Institute, 5-9-1 Shirokane, Minato-ku, Tokyo 108</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author><author><name sortKey="Kurata, Takeshi" sort="Kurata, Takeshi" uniqKey="Kurata T" first="Takeshi" last="Kurata">Takeshi Kurata</name><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Pathology, National Institute of Health, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Vaccine</title><title level="j" type="abbrev">JVAC</title><idno type="ISSN">0264-410X</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1994">1994</date><biblScope unit="volume">12</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="310">310</biblScope><biblScope unit="page" to="316">316</biblScope></imprint><idno type="ISSN">0264-410X</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0264-410X</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Antigenic</term><term>Antigenic drift</term><term>Bronchoalveolar</term><term>Bronchoalveolar site</term><term>Bronchoalveolar wash</term><term>Bronchoalveolar washes</term><term>Challenge virus</term><term>Cholera</term><term>Cholera toxin</term><term>Drift virus vaccine</term><term>Drift viruses</term><term>Earliest virus</term><term>Earliest virus strains</term><term>Hin1</term><term>Immunization</term><term>Infection</term><term>Influenza</term><term>Influenza vaccine</term><term>Influenza virus infection</term><term>Influenza viruses</term><term>Inoculation</term><term>Intranasal</term><term>Intranasal vaccination</term><term>Intranasally</term><term>Latest virus strains</term><term>Lethal dose</term><term>Lung infection</term><term>Many changes</term><term>Mouse</term><term>Nasal</term><term>Nasal infection</term><term>Nasal site</term><term>Nasal vaccination</term><term>Nasal wash</term><term>Original antigenic</term><term>Other details</term><term>Other hand</term><term>Present results</term><term>Primary immunization</term><term>Primary inoculation</term><term>Primary vaccine</term><term>Regimen</term><term>Respiratory tract</term><term>Second antigen</term><term>Second immunization</term><term>Second inoculation</term><term>Second vaccine</term><term>Subsequent inoculation</term><term>Subtype</term><term>Tamura</term><term>Titre</term><term>Vaccinated</term><term>Vaccinated mice</term><term>Vaccination</term><term>Vaccine</term><term>Vaccine strains</term><term>Virus</term><term>Virus challenge</term><term>Virus infection</term><term>Virus strains</term><term>Virus titres</term><term>Virus vaccine</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: Attempts were made to formulate an inactivated influenza vaccine to provide effective cross-protection by intranasal vaccination in mice. Mice were immunized with a nasal site-restricted volume of various HA vaccines (split-product virus vaccines), prepared from some of the H1N1 subtype viruses which circulated in humans from 1934 to 1986, together with cholera toxin B subunit (CTB) as an adjuvant. Four weeks later, they were challenged intranasally with a lethal dose of the earliest H1N1 virus strain, A/PR/8/34 (PR8) or the latest virus strain, A/Yamagata/120/86 (Yamagata/86). The adjuvant-combined vaccines, prepared from drift H1N1 viruses, A/Kumamoto/37/79 and A/Bangkok/10/83, provided a higher degree of cross-protection against a challenge with Yamagata/86 than with PR8. A booster with another drift virus vaccine given 4 weeks after the primary vaccination increased the protection against Yamagata/86; the effect was higher when mice were vaccinated with a later strain as the second antigen than when boosted with PR8. These results suggest that vaccination with a later virus strain followed by another later strain in a two-dose nasal vaccination regimen gives effective cross-protection against the current epidemic virus strains.</div></front></TEI><affiliations><list><country><li>Japon</li></country><region><li>Région de Kantō</li></region><settlement><li>Tokyo</li></settlement></list><tree><country name="Japon"><region name="Région de Kantō"><name sortKey="Tamura, Shin Ichi" sort="Tamura, Shin Ichi" uniqKey="Tamura S" first="Shin-Ichi" last="Tamura">Shin-Ichi Tamura</name></region><name sortKey="Aizawa, Chikara" sort="Aizawa, Chikara" uniqKey="Aizawa C" first="Chikara" last="Aizawa">Chikara Aizawa</name><name sortKey="Asanuma, Hideki" sort="Asanuma, Hideki" uniqKey="Asanuma H" first="Hideki" last="Asanuma">Hideki Asanuma</name><name sortKey="Ito, Yuji" sort="Ito, Yuji" uniqKey="Ito Y" first="Yuji" last="Ito">Yuji Ito</name><name sortKey="Kurata, Takeshi" sort="Kurata, Takeshi" uniqKey="Kurata T" first="Takeshi" last="Kurata">Takeshi Kurata</name><name sortKey="Nagamine, Takashi" sort="Nagamine, Takashi" uniqKey="Nagamine T" first="Takashi" last="Nagamine">Takashi Nagamine</name><name sortKey="Yoshizawa, Keiko" sort="Yoshizawa, Keiko" uniqKey="Yoshizawa K" first="Keiko" last="Yoshizawa">Keiko Yoshizawa</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001E03 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001E03 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= H2N2V1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:8D1DC3B6C29BAF110C167CE2FC616DC687931CE3
|texte= Formulation of inactivated influenza vaccines for providing effective cross-protection by intranasal vaccination in mice
}}
| This area was generated with Dilib version V0.6.33. |  |